105 related articles for article (PubMed ID: 3136116)
1. The mechanism of acquired resistance to cisplatin by a human ovarian cancer cell line.
Kikuchi Y; Iwano I; Miyauchi M; Kita T; Oomori K; Kizawa I; Sugita M; Tenjin Y
Jpn J Cancer Res; 1988 May; 79(5):632-5. PubMed ID: 3136116
[TBL] [Abstract][Full Text] [Related]
2. [Establishment of a cisplatin-resistant human ovarian cancer cell line and the mechanism of resistance].
Kikuchi Y; Iwano I; Miyauchi M; Kita T; Kizawa I; Oomori K; Kato K
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Mar; 40(3):379-83. PubMed ID: 3361190
[TBL] [Abstract][Full Text] [Related]
3. Possible mechanisms of resistance to cis-diamminedichloroplatinum (II) of human ovarian cancer cells.
Kikuchi Y; Iwano I; Miyauchi M; Kita T; Sugita M; Tenjin Y; Nagata I
Jpn J Cancer Res; 1990; 81(6-7):701-6. PubMed ID: 2119370
[TBL] [Abstract][Full Text] [Related]
4. Restorative effects of calmodulin antagonists on reduced cisplatin uptake by cisplatin-resistant human ovarian cancer cells.
Kikuchi Y; Iwano I; Miyauchi M; Sasa H; Nagata I; Kuki E
Gynecol Oncol; 1990 Nov; 39(2):199-203. PubMed ID: 2227596
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a cisplatin-resistant human ovarian cancer cell line.
Kikuchi Y; Miyauchi M; Kizawa I; Oomori K; Kato K
J Natl Cancer Inst; 1986 Dec; 77(6):1181-5. PubMed ID: 3467111
[TBL] [Abstract][Full Text] [Related]
6. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
7. [Reduced cisplatin-uptake by cisplatin-resistant human ovarian cancer cells].
Kikuchi Y; Iwano I; Miyauchi M
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2895-8. PubMed ID: 3178239
[TBL] [Abstract][Full Text] [Related]
8. [Drug resistant mechanisms of platinum derivatives in a human cisplatin resistant ovarian cancer cell line].
Nishiya I; Yoshizumi N; Fujiwara J; Kagabu T
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2871-81. PubMed ID: 3178236
[TBL] [Abstract][Full Text] [Related]
9. Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells.
Kikuchi Y; Hirata J; Yamamoto K; Ishii K; Kita T; Kudoh K; Tode T; Nagata I; Taniguchi K; Kuwano M
Jpn J Cancer Res; 1997 Feb; 88(2):213-7. PubMed ID: 9119751
[TBL] [Abstract][Full Text] [Related]
10. Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells.
Kamazawa S; Kigawa J; Minagawa Y; Itamochi H; Shimada M; Takahashi M; Sato S; Akeshima R; Terakawa N
Oncology; 2000 Nov; 59(4):329-35. PubMed ID: 11096346
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin.
Kudoh K; Kikuchi Y; Hiramatsu H; Hirata J; Yamamoto K; Kita T; Nagata I
Eur J Cancer; 1997 Jan; 33(1):122-8. PubMed ID: 9071911
[TBL] [Abstract][Full Text] [Related]
12. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray.
Sakamoto M; Kondo A; Kawasaki K; Goto T; Sakamoto H; Miyake K; Koyamatsu Y; Akiya T; Iwabuchi H; Muroya T; Ochiai K; Tanaka T; Kikuchi Y; Tenjin Y
Hum Cell; 2001 Dec; 14(4):305-15. PubMed ID: 11925933
[TBL] [Abstract][Full Text] [Related]
13. [The mechanism of resistance and its circumvention of cisplatin-resistant human ovarian cancer cells].
Kikuchi Y; Iwano I; Miyauchi M; Kita T; Kuki E; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1348-52. PubMed ID: 2584813
[TBL] [Abstract][Full Text] [Related]
14. [Cancer chemo-endocrine therapy and its cell biological basis].
Nishiya I
Hum Cell; 1998 Sep; 11(3):109-14. PubMed ID: 10086273
[TBL] [Abstract][Full Text] [Related]
15. cis-Diamminedichloroplatinum-resistant cell lines derived from human epithelial ovarian carcinoma express increased susceptibility to angiogenesis inhibitor TNP-470.
Tamura M; Takakuwa K; Tanaka K
Gynecol Oncol; 2004 Feb; 92(2):530-6. PubMed ID: 14766244
[TBL] [Abstract][Full Text] [Related]
16. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
Nonaka M; Itamochi H; Kawaguchi W; Kudoh A; Sato S; Uegaki K; Naniwa J; Sato S; Shimada M; Oishi T; Terakawa N; Kigawa J; Harada T
Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985
[TBL] [Abstract][Full Text] [Related]
17. [Cytokinetic effects of cisplatin on cisplatin-resistant ovarian cancer cell lines].
Sasa H; Kikuchi Y; Hisano A; Ishii K; Nagata I; Kawai T; Aida S; Sugita M; Sugishita T; Tenjin Y
Hum Cell; 1992 Dec; 5(4):384-91. PubMed ID: 1304801
[TBL] [Abstract][Full Text] [Related]
18. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
Minagawa Y; Kigawa J; Itamochi H; Terakawa N
Hum Cell; 2001 Sep; 14(3):237-43. PubMed ID: 11774743
[TBL] [Abstract][Full Text] [Related]
19. [In vitro drug-resistance decrease of ovarian cancer cells].
Lu SM
Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):348-51, 383. PubMed ID: 2282862
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
